Inhibrx Biosciences shares rise before Phase 2 cancer drug data
Updated
Updated · MarketWatch · May 8
Inhibrx Biosciences shares rise before Phase 2 cancer drug data
4 articles · Updated · MarketWatch · May 8
The stock gained 6.4% to $142.90 after hours after closing up 7.9% at $134.35, ahead of a Monday 8:30 a.m. ET webcast.
The company plans to present Phase 2 results for INBRX-106 in metastatic or unresectable recurrent head and neck squamous cell carcinoma.
INBRX-106, a hexavalent OX40 agonist, is being tested with pembrolizumab against pembrolizumab alone, and Inhibrx shares have climbed more than 1,000% over 52 weeks.
Can Inhibrx's cancer drug justify its 1000% stock surge, or will it repeat the failures of similar therapies?
With dozens of new cancer trials, is this drug the breakthrough that head and neck cancer patients need?